World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
58
Citations
19941
World Ranking
3462
National Ranking
1606

David Wofsy publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where David Wofsy sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 176 publications — 25th percentile

25% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

David Wofsy D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where David Wofsy sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 58 D-Index — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

David Wofsy is affiliated with the University of California, San Francisco in the United States. Their research primarily focuses on medicine, with a significant emphasis on immunology and microbiology. Within these fields, the subfields of rheumatology and immunology comprise the largest shares of their work, further extending into nephrology, hepatology, and artificial intelligence.

The main topics addressed in their scholarly activities include systemic lupus erythematosus research, atherosclerosis and cardiovascular diseases, renal diseases and glomerulopathies, liver diseases and immunity, T-cell and B-cell immunology, seismology and earthquake studies, and immune cells in cancer.

Several recent papers highlight their contributions to the understanding of lupus nephritis and systemic lupus erythematosus. These include:

  • Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (2020, Arthritis & Rheumatology)
  • Integrated urine proteomics and renal single-cell genomics identify an IFN-γ response gradient in lupus nephritis (2020, JCI Insight)
  • Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis (2021, Arthritis & Rheumatology)
  • European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance (2021, Annals of the Rheumatic Diseases)
  • Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities (2020, Annals of the Rheumatic Diseases)

Frequent coauthors associated with David Wofsy include Betty Diamond, Peter Izmirly, Jill P. Buyon, Diane L. Kamen, and Andrea Fava.

Wofsy has published extensively in several prominent venues, including:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Arthritis & Rheumatology
  • Annals of the Rheumatic Diseases
  • Lara D. Veeken
  • UNC Libraries

Best Publications

  • 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

    Martin Aringer;Karen Costenbader;David Daikh;Ralph Brinks

  • Treatment of murine lupus with CTLA4Ig.

    Barbara K. Finck;Peter S. Linsley;David Wofsy

  • The immune cell landscape in kidneys of patients with lupus nephritis

    Arnon Arazi;Deepak A Rao;Celine C Berthier;Anne Davidson

  • Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.

    D Wofsy;W E Seaman

  • Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.

    Kenneth C. Kalunian;John C. Davis;Joan T. Merrill;Mark C. Totoritis

  • Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.

    Maria Dall'Era;Eliza Chakravarty;Daniel Wallace;Mark Genovese

  • Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

    David Isenberg;Gerald B. Appel;Gabriel Contreras;Mary A. Dooley

  • INTERLEUKIN 6 PROMOTES MURINE LUPUS IN NZB/NZW F1 MICE

    B K Finck;B Chan;D Wofsy

  • Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells.

    J A Ledbetter;P J Martin;C E Spooner;D Wofsy

  • Treatment of Lupus Nephritis with Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study

    Anca Askanase;Margie Byron;Lynette Keyes-Elstein

  • Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

    David Isenberg;Caroline Gordon;Daiana Licu;Samuel Copt

  • Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.

    D Wofsy;W E Seaman

  • Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene.

    D Wofsy;E D Murphy;J B Roths;M J Dauphinée

  • PD-1hiCXCR5– T peripheral helper cells promote B cell responses in lupus via MAF and IL-21

    Alexandra V. Bocharnikov;Joshua Keegan;Vanessa S. Wacleche;Ye Cao

  • Treatment of murine lupus with monoclonal anti-T cell antibody.

    D Wofsy;J A Ledbetter;P L Hendler;W E Seaman

  • Interleukin 2 deficiency is a common feature of autoimmune mice.

    M J Dauphinée;S B Kipper;D Wofsy;N Talal

  • Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.

    David I. Daikh;Barbara K. Finck;Barbara K. Finck;Peter S. Linsley;Diane Hollenbaugh

  • Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice

    Caroline Gordon;Caroline Gordon;Gerald E. Ranges;John S. Greenspan;David Wofsy;David Wofsy

  • Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide

    David I. Daikh;David Wofsy

  • Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.

    John C. Davis;Mark C. Totoritis;J. A. Y. Rosenberg;Thomas A. Sklenar

  • Induction of immune tolerance by administration of monoclonal antibody to L3T4.

    N L Gutstein;W E Seaman;J H Scott;D Wofsy

Frequent Co-Authors

Betty Diamond
Betty Diamond Feinstein Institute for Medical Research
David Jayne
David Jayne University of Cambridge
Caroline Gordon
Caroline Gordon University of Birmingham
Karen H. Costenbader
Karen H. Costenbader Brigham and Women's Hospital
William E. Seaman
William E. Seaman University of California, San Francisco
Dimitrios T. Boumpas
Dimitrios T. Boumpas National and Kapodistrian University of Athens
Rosalind Ramsey-Goldman
Rosalind Ramsey-Goldman Northwestern University
Anne Davidson
Anne Davidson Feinstein Institute for Medical Research
Nir Hacohen
Nir Hacohen Harvard University
David A. Hildeman
David A. Hildeman Cincinnati Children's Hospital Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related online degrees can open diverse career pathways in healthcare and research. Transitioning from a Family Nurse Practitioner to a more specialized role often requires targeted education, such as an fnp to acute care certification, which equips nurses to handle complex clinical situations in acute settings.

Accelerated programs are popular among professionals seeking faster entry into advanced practice roles. Many choose a nurse practitioner accelerated program for its focused curriculum and flexibility, allowing them to gain advanced clinical skills alongside immunology expertise.

For those without a nursing background, the best online option is often a Bachelor of Science in Nursing (BSN). Resources highlighting the best online bsn programs for non nurses make it easier to find accessible, high-quality programs that pave the way to immunology-related nursing careers.

Additionally, if you're looking for quicker access into nursing, researching the easiest accelerated nursing programs can help identify pathways that fit your schedule and academic profile, facilitating a smooth transition into the healthcare field with a focus on immunology.

Best Scientists Citing David Wofsy

Trending Scientists

Recently Published Articles